Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis DOI Creative Commons
Giovanni Vita, Angelantonio Tavella, Giovanni Ostuzzi

et al.

Therapeutic Advances in Psychopharmacology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 1, 2024

Background: Long-acting injectable antipsychotics (LAIs) have advantages over oral (OAPs) in preventing relapse and hospitalization chronically ill patients with schizophrenia-spectrum disorders (SSDs), but evidence first-episode/recent-onset, that is, early-phase-SSDs is less clear. Objectives: To assess the relative medium- long-term efficacy safety of LAIs versus OAPs maintenance treatment early-phase SSDs. Method: We searched major electronic databases for head-to-head randomized controlled trials (RCTs) comparing early-phase-SSDs. Design: Pairwise, random-effects meta-analysis. Relapse/hospitalization acceptability (all-cause discontinuation) measured at study-endpoint were co-primary outcomes, calculating risk ratios (RRs) their 95% confidence intervals (CIs). Subgroup analyses sought to identify factors moderating differences or between OAPs. Results: Across 11 RCTs ( n = 2374, median age 25.2 years, males 68.4%, illness duration 45.8 weeks) lasting 13–104 (median 78) weeks, no significant emerged relapse/hospitalization prevention (RR 0.79, 95%CI 0.58–1.06, p 0.13) 0.92, 0.80–1.05, 0.20). The included highly heterogeneous regarding methodology patient populations. outperformed studies stable 0.65, 0.45–0.92), pragmatic design 0.67, 0.54–0.82), strict intent-to-treat approach 0.64, 0.52–0.80). Furthermore, associated better schizophrenia only 0.87, 0.79–0.95), longer 0.88, 0.80–0.97), unstable 0.89, 0.81–0.99) allowed OAP supplementation 0.90, 0.81–0.99). Conclusion: did not differ significantly prevention/hospitalization acceptability. However, nine subgroup analyses, superior EP-SSDs indicators higher quality and/or (four analyses) reduced all-cause discontinuation (five analyses), without any instance superiority LAIs. More high-quality are needed. Trial registration: CRD42023407120 (PROSPERO).

Language: Английский

Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review DOI
Marco Solmi, Alessandro Miola, Federico Capone

et al.

Expert Opinion on Drug Safety, Journal Year: 2024, Volume and Issue: 23(10), P. 1249 - 1269

Published: Sept. 3, 2024

People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute adverse cardiovascular outcomes.

Language: Английский

Citations

6
Psychopharmacology in children and adolescents: unmet needs and opportunities DOI
Samuele Cortese, Diane Purper‐Ouakil,

Alan Apter

et al.

The Lancet Psychiatry, Journal Year: 2023, Volume and Issue: 11(2), P. 143 - 154

Published: Dec. 7, 2023

Language: Английский

Citations

16
The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review DOI Creative Commons
Andrea Fiorillo, Gaia Sampogna, Umberto Albert

et al.

Brain Sciences, Journal Year: 2024, Volume and Issue: 14(3), P. 225 - 225

Published: Feb. 28, 2024

Background: Schizophrenia is a severe mental disorder characterized by positive, negative, affective, and cognitive symptoms. Affective symptoms in patients with schizophrenia have traditionally been overlooked or even neglected because they are not considered as fundamental positive negative the choice of medication. Methods: This paper aims to systematically evaluate efficacy safety lurasidone treatment depressive schizophrenia. Results: Lurasidone appears be particularly effective on symptomatology while also alleviating associated illness. Conclusions: The treating first-episode psychosis who present predominant suggests that this medication may valuable option only for established cases but individuals early stages good tolerability an important factor positively influence decisions.

Language: Английский

Citations

5
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder DOI Creative Commons
Elliot Hampsey, Luke A. Jelen, Allan H. Young

et al.

Expert Opinion on Emerging Drugs, Journal Year: 2024, Volume and Issue: 29(3), P. 193 - 204

Published: April 29, 2024

Major depression is a common, disabling mental health condition associated with the highest disease burden for any neuropsychiatric disorder worldwide, according to WHO. Due imperfect efficacy and tolerability profiles of existing treatments, investigational compounds in novel treatment classes are needed. Opioid-receptor antagonists potential new class treatments currently under investigation. depressive first overviewed. Existing both their mechanisms action place within antidepressant space, discussed herein. Then, profile Aticaprant wider context kappa-opioid antagonism focus. Early evidence indicates that may possess desirable pharmacodynamic pharmacokinetic properties. A lack convincing data at time writing precludes definitive statement on its as an antidepressant.

Language: Английский

Citations

5
Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis DOI Creative Commons
Giovanni Vita, Angelantonio Tavella, Giovanni Ostuzzi

et al.

Therapeutic Advances in Psychopharmacology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 1, 2024

Background: Long-acting injectable antipsychotics (LAIs) have advantages over oral (OAPs) in preventing relapse and hospitalization chronically ill patients with schizophrenia-spectrum disorders (SSDs), but evidence first-episode/recent-onset, that is, early-phase-SSDs is less clear. Objectives: To assess the relative medium- long-term efficacy safety of LAIs versus OAPs maintenance treatment early-phase SSDs. Method: We searched major electronic databases for head-to-head randomized controlled trials (RCTs) comparing early-phase-SSDs. Design: Pairwise, random-effects meta-analysis. Relapse/hospitalization acceptability (all-cause discontinuation) measured at study-endpoint were co-primary outcomes, calculating risk ratios (RRs) their 95% confidence intervals (CIs). Subgroup analyses sought to identify factors moderating differences or between OAPs. Results: Across 11 RCTs ( n = 2374, median age 25.2 years, males 68.4%, illness duration 45.8 weeks) lasting 13–104 (median 78) weeks, no significant emerged relapse/hospitalization prevention (RR 0.79, 95%CI 0.58–1.06, p 0.13) 0.92, 0.80–1.05, 0.20). The included highly heterogeneous regarding methodology patient populations. outperformed studies stable 0.65, 0.45–0.92), pragmatic design 0.67, 0.54–0.82), strict intent-to-treat approach 0.64, 0.52–0.80). Furthermore, associated better schizophrenia only 0.87, 0.79–0.95), longer 0.88, 0.80–0.97), unstable 0.89, 0.81–0.99) allowed OAP supplementation 0.90, 0.81–0.99). Conclusion: did not differ significantly prevention/hospitalization acceptability. However, nine subgroup analyses, superior EP-SSDs indicators higher quality and/or (four analyses) reduced all-cause discontinuation (five analyses), without any instance superiority LAIs. More high-quality are needed. Trial registration: CRD42023407120 (PROSPERO).

Language: Английский

Citations

5